Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$77,950.00+1.53%ETH$2,497.04+1.50%GOLD$4,405.80+0.14%OIL$96.70-0.55%
Smart Investors Daily
KN

OTC · KNBWY

Kirin Holdings Company, Limited

Consumer Defensive · Beverages - Alcoholic

$18.61

Up+$0.29 (+1.58%)

Updated Sep 18, 2026, 1:06 PM

SID Score

5.0/10

Composite research score

Smart Money

53/100

Neutral

Market cap
12.35B
P/E ratio
34.91
Dividend yield
2.62%
52-week range
— – —
Volume
5.04K
Avg. volume
33.88K

Price performance

KNBWY price history

1M range · 0 trading sessions · Daily adjusted prices

KNBWY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest KNBWY news

The latest Smart Investors Daily articles mentioning KNBWY.

Stock researchCompany · Overview

KNBWY research

Overview

Company profile and research snapshot.

Company profile

KIRIN HLDGS CO LTD S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 28, 2026

Jamieson Wellness Inc. Announces Filing of Management Information Circular for its Special Meeting of Shareholders to Approve the Proposed Plan of Arrangement with Kirin Holdings Company, Limited

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) is pleased to announce that the Company has filed its management information circular (the "Circular") and related proxy materials for its special meeting (the "Meeting") of the holders (the "Shareholders") of common shares of Jamieson Wellness (the "Shares"), which will be conducted via live audio webcast over the internet at https://virtual-meetings.tsxtrust.com/1980 using the Meeting password "jamieson2026" (case sensit

globenewswire.com · Dec 2, 2025

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura's collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By